A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)
Open Access
- 28 October 2003
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 89 (9) , 1766-1775
- https://doi.org/10.1038/sj.bjc.6601346
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- The epidermal growth factor receptor–tyrosine kinase: A promising therapeutic target in solid tumorsSeminars in Oncology, 2003
- Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human esophageal cancer cellsInternational Journal of Cancer, 2002
- Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor ReceptorPublished by Elsevier ,2002
- Meta‐iodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cellsInternational Journal of Cancer, 2002
- ZD1839: targeting the epidermal growth factor receptor in cancer therapyExpert Opinion on Investigational Drugs, 2002
- Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growthAnnals of Oncology, 2002
- Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferationBritish Journal of Surgery, 2001
- Expression of c-Myc, TGF-α and EGF-Receptor in Sporadic Medullary Thyroid CarcinomaActa Oncologica, 1997
- Mitochondrial control of nuclear apoptosis.The Journal of Experimental Medicine, 1996
- Increased epidermal growth factor receptor in multidrug‐resistant human neuroblastoma cellsJournal of Cellular Biochemistry, 1988